KRAS and Immune Checkpoint Inhibitors-Serendipity Raising Expectations

J Thorac Oncol. 2019 Jun;14(6):951-954. doi: 10.1016/j.jtho.2019.03.004.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung Neoplasms*
  • Motivation
  • Programmed Cell Death 1 Receptor
  • Proto-Oncogene Proteins p21(ras)

Substances

  • KRAS protein, human
  • Programmed Cell Death 1 Receptor
  • Proto-Oncogene Proteins p21(ras)